<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127582">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01680575</url>
  </required_header>
  <id_info>
    <org_study_id>NEPACA-OVCA</org_study_id>
    <nct_id>NCT01680575</nct_id>
  </id_info>
  <brief_title>Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer</brief_title>
  <official_title>Development of a Risk Model Predicting Chemotherapy-induced Grade 3-4 Neutropenia by Paclitaxel/Carboplatin in Epithelial Ovarian Cancer: Prospective Observational Study for Model Development and Retrospective Study for Validation of Developed Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Asan Medical Center Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a robust prediction model to predict the occurrence of grade 3-4 neutropenia
      induced by adjuvant paclitaxel/carboplatin chemotherapy in patients with epithelial ovarian
      cancer and to validate this model.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Risk prediction model for grade 3-4 chemotherapy induced neutropenia</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The association between mannose-binding lectin 2 gene SNP and neutropenia</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>This cohort is a prospective cohort to develop a risk prediction model. This cohort include patients who underwent staging operation or debulking operation for epithelial ovarian cancer and are planned to receive ajuvant chemotherapy with paclitaxel/carboplatin up to 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Validation cohort</arm_group_label>
    <description>This is a retrospective cohort for validation of a risk prediction model developed using training cohort.
This is consisted with 600 patients with epithelial ovarian cancer who received adjuvant chemotherapy with paclitaxel/carboplatin after staging operation or debulking operation.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Training cohort (prospective cohort): Patients with epithelial ovarian cancer who
        underwent staging operation or debulking surgery at university hospital and who are
        planned to receive adjuvant chemotherapy with paclitaxel and carboplatin.

        Validation cohort (retrospective cohort): Patients with epithelial ovarian cancer who
        received adjuvant chemotherapy with paclitaxel and carboplatin after staging operation or
        debulking operation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with FIGO stage I-IV epithelial ovarian cancer after staging or debulking
             surgery

          -  Patients who is planned to receive (prospective cohort) ro who received
             (retrospective cohort) adjuvant chemotherapy with paclitaxel and carboplatin

          -  Patients who have signed approved informed consent

        Exclusion Criteria:

          -  Uncontrolled medical disease

          -  Active infectious disease

          -  Previous pelvic radiation therapy

          -  Previous chemotherapy (prospective cohort)

          -  Patients with disease which can cause neutropenia

          -  Patients who will receive other targeted therapy or immunotherapy during adjuvant
             therapy (prospective cohort).

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-Yeol Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong-Yeol Park, M.D., Ph.D.</last_name>
    <phone>82-2-3010-3646</phone>
    <email>catgut1-0@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong-Yeol Park, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 8, 2012</lastchanged_date>
  <firstreceived_date>September 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Jeong-Yeol Park</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Neutropenia</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Epithelial ovarian cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
